Summary
This multi-centre, multi-laboratory study examined prognostic biomarkers in invasive bladder cancer across 1058 radical cystectomy patients. The research compared FGFR3 mutation status against established markers (P53 and KI-67 expression) to evaluate their utility in predicting patient outcomes. The findings as suggested by the title contribute to the growing evidence base for molecular stratification in bladder cancer prognosis.
UK applicability
The study's findings on prognostic biomarkers may inform UK urological oncology practice and patient stratification protocols, though applicability would depend on NHS adoption of FGFR3 testing and integration with existing P53/KI-67 assessment frameworks in UK pathology services.
Key measures
FGFR3 mutation status, P53 expression, KI-67 expression, recurrence-free survival, cancer-specific survival, overall survival
Outcomes reported
The study evaluated the prognostic value of FGFR3 mutation status compared to P53 and KI-67 expression in predicting outcomes in patients with invasive bladder cancer treated by radical cystectomy. The analysis involved 1058 patients across multiple centres and laboratories.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.